Stock Financial Ratios


JUNO / Juno Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price58.64
Volume1,422,100.00
Market Cap ($M)5,955.95
Enterprise Value ($M)4,333.52
Book Value ($M)1,077.70
Book Value / Share10.62
Price / Book5.19
NCAV ($M)1,234.57
NCAV / Share12.17
Price / NCAV4.17
Income Statement (mra) ($M)
Revenue79.36
EBITDA-255.60
Net Income-245.58
Balance Sheet (mrq) ($M)
Cash & Equivalents449.84
Cash / Share4.43
Assets1,534.49
Liabilities386.72
Quick Ratio6.72
Current Ratio6.72
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.23
Return on Assets (ROA)-0.18
Return on Equity (ROE)-0.23
Identifiers and Descriptors
CUSIP48205A109
Central Index Key (CIK)1594864
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
048205A10
48205A909
48205A959
Share Statistics
Common Shares Outstanding (M)114.17
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Assets Per Share15.12
Accounts Receivable Per Share0.34
Treasury Stock Per Share0.00
Intangibles Per Share0.76
Equity Per Share11.31
Cash And Equivalents Per Share4.43
Liabilities Other Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Assets Other Non Current Per Share0.04
Liabilities And Stock Equity Per Share15.12
Minority Interest Per Share0.00
Liabilities Per Share3.81
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Property Plant And Equipment Net Per Share1.30
Inventory Raw Materials Per Share0.00
Assets Current Per Share9.58
Assets Other Current Per Share0.00
Cash Per Share4.43
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Retained Earnings Per Share-11.16
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Long Term Debt Per Share0.10
Liabilities Current Per Share2.01
Goodwill Per Share2.18
Property Plant And Equipment Per Share1.30
Inventory Per Share0.00
Debt Per Share0.11
Deferred Income Tax Liabilities Per Share0.02
Additional Paid In Capital Per Share22.44

Related News Stories

Juno Therapeutics Back With New Data - Slingshot Insights' Idea Of The Month

9h seekingalpha
We have extended our partnership with Cheddar TV to produce a Seeking Alpha 'Idea of the Month' segment with Marketplace authors. (5-0)

Biotech ETFs: What Lies Ahead?

2017-11-13 zacks
So far, it’s been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19.6% year to date. This is in sharp contrast to last year’s performance when the Index was down 19.1% with several factors including the drug pricing controversy weighing on the sector. (177-0)

Editas Medicine's (EDIT) CEO Katrine Bosley on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon and welcome to Editas Medicine’s Third Quarter 2017 Financial Results and Update Conference Call. [Operator Instructions]. Please be advised that this call is being recorded at Editas Medicine’s request. I would now like to turn the call over to the Editas Medicine team. Please proceed. (19-0)

Featured Company News - US FDA Clears Sarepta Therapeutics' IND Application for GALGT2 Gene Therapy Program; Nationwide Children's Hospital Prepared to Initiate Phase-1/2a Clinical Trials for Patients with DMD

2017-11-07 accesswire
LONDON, UK / ACCESSWIRE / November 7, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Sarepta Therapeutics, Inc. (NASDAQ: SRPT), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=SRPT. The Company announced on November 03, 2017, that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the GALGT2 gene therapy program. (39-0)

AveXis: Revolutionary Cure For SMA1 Enters Phase III Trials With Excitement Mounting

2017-11-02 seekingalpha
Pricing of the treatment is creating excitement among shareholders - strong potential returns over the next 3 years. (81-1)

CUSIP: 48205A109